Hashimoto's Thyroiditis Research Reagents

Hashimoto's thyroiditis (HT) is the most common autoimmune disease and the leading cause of hypothyroidism in iodine-sufficient regions, affecting up to 5% of the general population with a strong female predominance. The disease is characterized by progressive lymphocytic infiltration of the thyroid gland, follicular cell destruction, and fibrosis. Both cellular (cytotoxic T cell-mediated) and humoral (anti-TPO, anti-Tg autoantibodies) immune mechanisms drive thyroid destruction. Genetic susceptibility loci include HLA-DR3/DR5, CTLA-4, and PTPN22, with environmental triggers such as iodine excess, viral infections (HCV, SARS-CoV-2), and micronutrient imbalances (selenium deficiency) contributing to disease initiation.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Hashimoto's Thyroiditis Research Reagents — key pathogenic pathways and research targets including anti-TPO autoantibodies, T cell-mediated follicular destruction, TSHR, and thyroglobulin

Fig. 1 Key pathogenic pathways and research targets in Hashimoto's thyroiditis. Anti-TPO and anti-Tg autoantibodies, cytotoxic T cell-mediated follicular destruction, TSHR blocking antibodies, and thyroid hormone axis disruption. Key research targets highlighted in orange.

abinScience provides validated recombinant antibodies, monoclonal antibodies, and recombinant proteins for thyroid autoimmunity research, including anti-TPO, anti-thyroglobulin, anti-TSHR clones, and TSH detection antibodies with fluorescent conjugates. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

TPO (Thyroid Peroxidase) — Anti-TPO autoantibodies are the most sensitive serological marker for Hashimoto's thyroiditis, present in >90% of patients. TPO catalyzes thyroid hormone synthesis and is the primary autoantigen driving complement-mediated thyrocyte destruction. Recombinant anti-TPO antibodies (multiple clones: RI-34, RI-33, RI-8) with fluorescent conjugates (FITC, PE, APC, PerCP) support flow cytometry, ELISA development, and epitope mapping.
→ Browse TPO antibodies & proteins

Thyroglobulin (Tg) — Anti-thyroglobulin autoantibodies are present in 60–80% of HT patients and serve as a complementary diagnostic marker alongside anti-TPO. In differentiated thyroid cancer follow-up, anti-Tg antibodies can interfere with serum Tg measurement, making antibody characterization critical for assay development. Monoclonal antibodies, recombinant antibodies, nanobodies, and recombinant mouse Tg protein are available.
→ Browse Thyroglobulin antibodies & proteins

TSHR (TSH Receptor) — While TSHR-stimulating antibodies define Graves' disease, TSHR-blocking antibodies are found in a subset of HT patients and contribute to hypothyroidism. Anti-TSHR recombinant antibodies (M22, K1-70, 3BD10, 1H7) with multiple conjugates support receptor binding assays, functional blocking studies, and differential diagnosis research between stimulating and blocking TSHR autoantibodies.
→ Browse TSHR antibodies & proteins

TSH (Thyroid-Stimulating Hormone) — Serum TSH is the primary biomarker for detecting hypothyroidism in Hashimoto's thyroiditis. Anti-TSH monoclonal antibodies (matched-pair clones: 1A307, 1A308, 1A309) support sandwich ELISA development and TSH immunoassay calibration for thyroid function testing research.
→ Browse TSH antibodies

References

1. Caturegli P, et al. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391-397. DOI

2. Ragusa F, et al. Hashimoto's thyroiditis: epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101367. DOI

3. Antonelli A, et al. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14(2):174-180. DOI